Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
It is designed as a once-weekly injectable treatment for obesity, working via amylin receptors rather than the GLP-1 pathway used by most current weight loss medications
FOXO4-DRI draws interest mainly from people focused on longevity and the deeper biology of aging, usually with one of these goals: What unites them is a goal, aging more slowly and staying functional longer, rather than this specific molecule
Research question Added amylin and fullness signaling Most relevant comparison page Cagrilintide + retatrutide stack guide Research question Mitochondrial and exercise-related signaling Most relevant comparison page Retatrutide + MOTS-C stack guide Research question GH and IGF-1 response during a calorie deficit Most relevant comparison page Advanced Recomp Stack guide Research question GHRH and visceral-fat research Most relevant comparison page Tesamorelin evidence and label context Research question Highest direct evidence with the fewest variables Most relevant comparison page Retatrutide standalone protocol Why More Compounds Mean More Uncertainty A stack can make a research design look more complete while making the results harder to read
Bottiglieri T
Recommended Guidelines Dosage: Always stick to dermatologically prescribed doses, whether in oral or injectable form
